cell lineages, with most cells expressing cyclin D3 and either D1 or D2 (Sherr, 1993) . No differential roles for these cyclins have yet been recognized and evidence from mice expressing only a single D-type cyclin suggests that they are functionally redundant in mouse development (Ciemerych et al., 2002) . Two types of cyclin E (E1 and E2) exist, which show overlapping expression patterns in mouse tissues and can be co-overexpressed in human tumours (Geng et al., 2001) . Future research will elucidate whether any of their functions are distinct.
Mitotic cyclins A and B mediate progression through the S/G 2 /M phases. Cyclin A1 is expressed in meiosis and early embryogenesis, whereas cyclin A2 is found in proliferating somatic cells (Yang et al., 1997) . Cyclin B2 probably plays a role in Golgi remodelling during mitosis (Jackman et al., 1995) , while cyclin B1 controls other functions of this cyclin type. Additional cyclins exist (totalling around 16), for many of which binding partners and functions have yet to be identified.
At present, nine mammalian Cdks with known functions have been identified (Morgan, 1997) , only four of which (Cdk1, -2, -4 and -6) are directly involved in cell cycle control. Cdk7 contributes indirectly by acting as a Cdkactivating kinase (CAK) that phosphorylates other Cdks (see below). Since Cdk expression levels are relatively constant throughout the cell cycle, the primary regulation of Cdk activity is governed by sequential synthesis, posttranslational modification and degradation of cyclins. D-type cyclins are short-lived proteins whose synthesis and assembly with Cdk4 or Cdk6 in G 1 is dependent on mitogenic signalling (Hitomi & Stacey, 1999) . Cyclin D/Cdk activity persists through the first and subsequent cycles as long as mitogenic stimulation continues (Matsushime et al., 1991) . Cyclin E protein levels peak at the G 1 /S progression, followed by an increase in cyclin A levels in the S phase. Both cyclin E and A interact with and activate Cdk2, while cyclin A can also bind Cdk1 (Lees & Harlow, 1993) . At the G 2 /M boundary, cyclin B levels increase, resulting in activation of its partner, Cdk1. This fluctuation in cyclin expression and resultant oscillation in Cdk activity ( Fig. 1) form the basis of a coordinated cell cycle progression and a platform for more subtle regulatory controls.
Structure of cyclin and Cdk catalytic subunits
Cyclins are a remarkably diverse family of proteins, ranging in size from about 35 to 90 kDa. Sequence homology is concentrated in a 100 amino acid stretch, known as the 'cyclin box', which is necessary for Cdk binding and activation (Kobayashi et al., 1992; Lees & Harlow, 1993) . Thus far, cyclin structures of bovine and human cyclin A, cyclin H and three viral cyclin D homologues have been described (Brown et al., 1995; Card et al., 2000; Jeffrey et al., 1995 Jeffrey et al., , 2000 Kim et al., 1996; Schulze-Gahmen et al., 1999) . A comparison of these structures suggests that the core of all cyclins contains two compact domains of five helices, called the 'cyclin fold' (Fig. 2) . The first helix bundle corresponds to the conserved cyclin box. This central fold is flanked by additional helices at the N and C termini, whose position and secondary structure vary in different cyclins.
Cdks are closely related in size (35-40 kDa) and sequence (>40 % identity) and have the same overall fold as other eukaryotic protein kinases. Monomeric Cdk2 consists of an N-terminal lobe rich in b-sheets (N lobe), a C-terminal lobe rich in a-helices (C lobe) and a deep catalytic cleft at the junction of the lobes (De Bondt et al., 1993) . Crystallized cyclin/Cdk6 shows a similar Cdk structure, suggesting that the structural features of Cdk2 are conserved in all Cdks (Jeffrey et al., 2000; Schulze-Gahmen & Kim, 2002) . The catalytic activity of the monomeric Cdk subunit is restrained by two mechanisms. First, a large flexible loop (T-loop) on the C-terminal lobe obstructs substrate binding at the catalytic cleft. Secondly, a stretch of helical amino acids in the N-terminal lobe (PSTAIRE helix), which contains residues required for ATP phosphate binding, is directed away from the cleft (De Bondt et al., 1993) (Fig. 2) .
v-Cyclin is a cyclin D homologue. The viral homologue of cellular cyclin D encoded by KSHV is called K cyclin or viral cyclin (v-cyclin). The v-cyclin sequence shows around 53 % sequence similarity to cyclin D2, with the highest level of homology around the cyclin box (Li et al., 1997) . This, together with the ability of v-cyclin to bind and activate Cdk4 and Cdk6 and direct their kinase activity towards Rb (Chang et al., 1996; Godden-Kent et al., 1997; Li et al., 1997) , shows that v-cyclin resembles Dtype cyclins both at the structural and at the functional level.
Regulatory mechanisms governing cyclin/Cdk activity

Cdk activation by cyclin binding
Cdk activity is regulated through multiple mechanisms, the primary mechanism being its binding to the cyclin subunit. The crystal structure of the human Cdk2/cyclin A1 complex revealed that cyclin binding changes the Cdk2 T-loop structure and position such that it no longer obstructs the catalytic cleft. Cyclin binding also rotates the PSTAIRE helix and moves it into the catalytic cleft, resulting in the correct positioning of the ATP-binding catalytic residues (Jeffrey et al., 1995) (Fig. 2) . Although the major cyclin/Cdk binding and structural characteristics are conserved, variations in the length of the Cdk PSTAIRE helix and position of the N-terminal cyclin helix exist (Jeffrey et al., 2000; Kim et al., 1996) . This may underlie the specificity of Cdk4/6 for D-type cyclins, Cdk2 for cyclins A and E and Cdk1 for cyclin B.
v-Cyclin preferentially interacts with Cdk6. In vitro binding and kinase assays indicate that v-cyclin mainly forms active complexes with Cdk6 (Godden-Kent et al., 1997; Li et al., 1997) . The preference for Cdk6 is remarkable in light of the KSHV host cell repertoire, since lymphoid cells express relatively high levels of Cdk6 and cyclin D/Cdk6 activity predominates in such cells (Meyerson & Harlow, 1994) . Cdk6 expression is also detectable in KS lesions (Ojala et al., 1999) .
v-Cyclin/Cdk6 complexes show enhanced kinase activity. v-Cyclin/Cdk6 complexes show enhanced kinase activity towards their substrates as measured by in vitro kinase assays when compared with cyclin D/Cdk complexes (Jeffrey et al., 2000; Li et al., 1997; Swanton et al., 1999) . This could be the result of increased interactions between v-cyclin and Cdk, with the more stable active conformation accounting for an increased kinase activity (Jeffrey et al., 2000) .
v-Cyclin/Cdk6 complexes phosphorylate Cdk2-type substrates. v-Cyclin/Cdk6 complexes phosphorylate an extended array of substrates that are not normally targets of cyclin D/Cdk6. These include the cyclin E/Cdk2 targets p27, histone H1 and Cdc25A (Ellis et al., 1999; Mann et al., 1999) and the cyclin A/Cdk2 targets of the replication machinery, Cdc6 and Orc1 (Laman et al., 2001) . The activity of v-cyclin/Cdk6 therefore mimics the combined activities of G 1 and S phase cyclin/Cdk complexes. What explains this expanded substrate specificity? The substrate specificity of Cdk2 differs depending on its binding to cyclin E or A, implying that the cyclin subunit is likely to contribute (Sarcevic et al., 1997; Zarkowska et al., 1997) . Indeed, substrates bind to a conserved binding groove on the cyclin, called the hydrophobic patch (Schulman et al., 1998) . Another potential determinant is the conformation of the catalytic site (Brown et al., 1999) . By inference, v-cyclin binding to substrates as well as the effect of v-cyclin on conformation of the Cdk6 catalytic cleft are likely to determine its substrate repertoire. Morgan (1997) and Jeffrey et al. (2000) . Cyclin binding to the Cdk subunit changes the catalytic cleft to an active conformation by removing the T-loop such that substrate can bind and by moving the PSTAIRE helix into the cleft so that ATP is bound properly. CAK phosphorylation of Cdk2 Thr-160 residue is counteracted by the Cdk-associated phosphatase, KAP. Wee1/Myt1 protein kinases phosphorylate Thr-14 and Thr-15 residues, which is counteracted by the Cdc25 phosphatase. Modifications in green represent Cdk activation events, modifications in red represent inhibitory events.
Regulation of Cdk activity by phosphorylation
Complete activation of Cdk activity is mediated by phosphorylation of a conserved threonine residue (Thr-160 in Cdk2, Thr-161 in Cdk1) in the T-loop by the CAK enzyme (Fig. 2) . The major mammalian candidate for CAK is the cyclin H/Cdk7/Mat1 complex (Nigg, 1996) . CAK phosphorylation moves the T-loop outwards, resulting in additional Cdk-cyclin contacts and probably increases potential for substrate binding (Russo et al., 1996b) . Dephosphorylation of this residue can be achieved by the Cdk-associated phosphatase, KAP (Poon & Hunter, 1995) .
In addition, Cdks undergo inhibitory phosphorylation on the Thr-14 and Tyr-15 residues located in the roof of the ATP phosphate-binding site (Fig. 2) . It is likely that this reduces the affinity for ATP, thereby preventing Cdk catalytic activity . Phosphorylation of these sites is mediated by the Wee1 and Myt1 protein kinases (Lew & Kornbluth, 1996) and dephosphorylation is carried out by phosphatases of the Cdc25 family. Cdc25A and B are active during G 1 /S and Cdc25C is the mitotic isoform. Not surprisingly, this extensive phosphorylation network is amenable to various regulatory mechanisms, which are central to the execution of cell cycle checkpoints.
Non-CAK-phosphorylated v-cyclin/Cdk6 complexes are active in vitro. Unlike D-type cyclin/Cdk complexes, v-cyclin/Cdk6 complexes do not require CAK phosphorylation to generate active holoenzymes in vitro (Child & Mann, 2001; Kaldis et al., 2001) , which renders v-cyclin function less dependent on host kinase activity compared with cyclin D. Activation is, however, incomplete, because non-CAK-phosphorylated v-cyclin/Cdk6 does not target the full range of retinoblastoma protein (Rb) phosphorylation sites and does not enable S-phase entry (Child & Mann, 2001 ).
Inhibition by Ink4-family proteins
The Ink4 family of Cdk inhibitors (CKIs) contains four members, named according to their molecular masses, p16 Ink4a , p15
Ink4b
, p18
Ink4c and p19 Ink4d (p16, p15, p18 and p19) and their ability to inhibit Cdk4. These CKIs specifically inhibit Cdk4 and Cdk6 and do not bind Cdk2 or Cdk1. Ink4 proteins are composed of multiple ankyrin repeats and bind to the non-catalytic side of Cdk4 and Cdk6 opposite the cyclin D binding site (Russo et al., 1998) . Binding of Ink4 inhibitors to Cdk4 or Cdk6 prevents Cdk interaction with cognate D-type cyclins: Ink4 binding induces allosteric changes by rotating the two Cdk4/6 lobes 15 u in the vertical axis, thus mislocating the cyclininteracting sequences and distorting the ATP binding site (Jeffrey et al., 2000) (Fig. 3) .
v-Cyclin/Cdk6 complexes are less susceptible to inhibition by Ink4 proteins. Ink4 proteins are unable to inhibit v-cyclin/Cdk6-driven kinase activity towards Rb in protein extracts from baculovirus-infected Spodoptera frugiperda (Sf9) cells (Swanton et al., 1997) . Insight into the lack of inhibition by Ink4 proteins was provided by the crystallization of the v-cyclin/Cdk6/p18 ternary complex (Jeffrey et al., 2000) . The authors showed that CAKphosphorylated Cdk6/v-cyclin complexes are resistant to inhibition by p18 and suggested that CAK phosphorylation of Cdk6 increases the interactions between the N and C lobes of Cdk6. This, together with increased interactions between v-cyclin and the Cdk6 C lobe could stabilize the active arrangement of the catalytic cleft and prevent its disruption upon Ink protein binding. In agreement with this, the interface of the HVS viral cyclin/Cdk6 complex is 20 % larger than in the cyclin A/Cdk2 complex (Schulze-Gahmen et al., 1999) .
Inhibition by Cip/Kip family proteins
Cdk inhibitors of the Cip/Kip family are more broadly acting Cdk inhibitors. This family consists of three members, p21
Cip1
, p27
Kip1 and p57 Kip1 (p21, p27 and p57). p21 and p27 are potent inhibitors of cyclin D-, Eand A-and weak inhibitors of cyclin B-associated kinase activity (el-Deiry et al., 1993; Gu et al., 1993; Noda et al., 1994; Xiong et al., 1993) . p57 is thought to be functionally analogous to other Cip/Kip proteins, but fewer studies have focused on p57.
The Cip/Kip family inhibitors can bind isolated cyclin and Cdk subunits independently, although their binding affinity for cyclin/Cdk complexes is higher (Chen et al., 1996; Harper et al., 1995; Lin et al., 1996; Toyoshima & Hunter, 1994) . The Cip/Kip N-terminal moiety is necessary and sufficient to bind to and inhibit Cdk complexes. This Nterminal region contains two subsections: a short motif required for cyclin binding (Cy1) and a more complex segment that binds the Cdk subunit (Chen et al., 1996; Fotedar et al., 1996) . The crystal structure of an N-terminal p27 peptide in complex with cyclin A/Cdk2 provided a breakthrough in our understanding of the inhibitory mechanism (Russo et al., 1996a) . The p27 peptide stretches across the top of the cyclin/Cdk complex in an extended conformation (Fig. 3) . The N-terminal part of the p27 peptide binds a conserved hydrophobic groove on the cyclin box. This p27/cyclin interaction is likely to serve as an anchor to facilitate subsequent p27/Cdk binding, since it does not require conformational changes. The C-terminal part of the peptide interacts with the upper Cdk lobe, disrupting the conformation of the ATP binding site. In addition, a p27 helix inserts into the catalytic cleft and prevents ATP binding. Together, these interactions disrupt any catalytic potential of the cyclin/Cdk complex.
Multiple experiments have indicated that p21 and p27 can associate with active cyclin D/Cdk complexes and may therefore act as assembly factors . However, p21/p272/2 cells proliferate and are susceptible to p16-mediated growth inhibition (Cheng et al., 1999) , implying that p21 and p27 are not strictly required for cyclin D/Cdk activity. Furthermore, the stability of cyclin D and Cdks is significantly reduced in the absence of p21 and p27 (Bagui et al., 2000; Cheng et al., 1999) , complicating assessment of the effect of Cip/Kip binding on cyclin D/Cdk complex activity. Purification and crystallization of the cyclin D/Cdk/CKI complex will clarify the properties of the holoenzyme.
v-Cyclin/Cdk6 complexes are less susceptible to inhibition by Cip/Kip proteins. Similar to Ink4 inhibitors, Cip/ Kip proteins are also unable to inhibit v-cyclin/Cdk6-driven kinase activity towards Rb in protein extracts from baculovirus-infected Sf9 cells (Swanton et al., 1997) . The resistance to Cip/Kip proteins correlates with the lack of p21/p27 binding to v-cyclin/Cdk complexes. This conclusion is supported by the superimposition of the cyclin A/p27 structure over the HVS viral cyclin structure (Schulze-Gahmen et al., 1999) . While the p27 binding pocket of cellular cyclins is highly conserved, viral cyclins contain substitutions in residues that are crucial for p27 binding. Notably, Glu-66 of cyclin D (Glu-220 of cyclin A), which forms a hydrogen bond and a salt bridge with p27, is substituted for Ser-60 in v-cyclin . This results in loss of the electronegative character of the p27 binding groove and reduces the number of possible contacts between v-cyclin and p27, together decreasing the likelihood of p27 binding to v-cyclin (Schulze-Gahmen et al., 1999; Swanton et al., 1999) .
Cyclin/Cdk localization
Since many critical cyclin/Cdk targets are nuclear proteins, nucleocytoplasmic shuttling is a means of regulating cyclin/Cdk activity . The G 1 /S cyclins A and E are expressed predominantly in the nucleus (Ohtsubo et al., 1995; Pines & Hunter, 1991) , consistent with their roles in DNA replication and S-phase progression. In contrast, cyclin B is exclusively cytoplasmic during G 1 /S, followed by a dramatic nuclear relocation upon mitotic entry (Takizawa & Morgan, 2000) . Differences (Jeffrey et al., 1995) , ternary p27/cyclin A/Cdk2 (Russo et al., 1996a) and p18/viral cyclin/Cdk6 (Jeffrey et al., 2000) complexes. The crystal structure of v-cyclin serves as a model for D-type cyclin structure, as cellular D-type cyclin could not be crystallized (Jeffrey et al., 2000) . A model of cyclin/Cdk inhibition by CKIs is deduced by comparing the structures of the three complexes (Jeffrey et al., 2000) . The Ink4 inhibitors bind to Cdk4 or Cdk6 and prevent their interaction with D-type cyclins by rotation of the Cdk lobes 156 in the vertical axis. Cip/Kip inhibitors bind both cyclin and Cdk subunits, which disrupts Cdk catalytic activity by disruption of the conformation of the Cdk subunit, the ATP binding site and the catalytic cleft. The T-loop is indicated in red and the PSTAIRE helix in green.
in the shuttling behaviour of these cyclins are a consequence of distinct nuclear import and export mechanisms and speeds (Jackman et al., 2002) .
Cyclin D/Cdk complexes accumulate in the nucleus throughout the G 1 phase but then relocate to the cytoplasm during the remainder of interphase (Baldin et al., 1993) . Since neither cyclins nor Cdks contain canonical nuclear localization sequences (NLSs), nuclear import may be mediated via their binding to NLS-containing proteins. Suggested cyclin D nuclear import factors are Cip/Kip proteins, which contain an NLS and promote cyclin D/Cdk nuclear accumulation (Cheng et al., 1999; LaBaer et al., 1997) . However, absence of both p21 and p27 does not abolish cyclin D1 nuclear import (Cheng et al., 1999) and, instead, p21 and p27 have been suggested to promote cyclin D1 nuclear accumulation via inhibition of a glycogen synthase kinase (GSK)-3b-triggered nuclear export mechanism (Alt et al., 2002) . Another candidate import factor is the p34 SEI-1 protein that binds to cyclin D1/Cdk4 complexes and contains an NLS (Sugimoto et al., 1999) . Yet another possibility is that cyclin D contains an unidentified NLS, as suggested for cyclin E .
How is nuclear accumulation of v-cyclin regulated? Cyclin D1 nuclear export is triggered upon GSK-3b-mediated phosphorylation of Thr-286 in cyclin D1 (Alt et al., 2002) . v-Cyclin does not contain a residue homologous to the cyclin D1 Thr-286 residue, perhaps implying that v-cyclin evades nuclear export. This could explain why nuclear accumulation of v-cyclin is pronounced (Child & Mann, 2001) , even though it does not bind p21/ p27 CKIs (Swanton et al., 1997) .
Cyclin/Cdk/CKI stability While Cdks are expressed constitutively and are relatively stable, cyclins are subject to regulated degradation. The degradation of cyclins is regulated by the ubiquitinproteasome system. Ubiquitination involves the covalent attachment of ubiquitin chains to lysine residues in the target protein, which promotes its recognition and degradation by the proteasome (Harper et al., 2002) (Fig. 4A) . Two ubiquitin ligases regulate cell cycle progression: the Skp/ Cullin/F-box (SCF) complex targets proteins at the G 1 /S/ G 2 phases and the anaphase-promoting complex (APC) acts at G 2 /M (Fig. 4B) . Target specificity of these ligases is governed by their binding to adaptor proteins. These comprise F-box sequence motif-containing proteins such as Skp2 in the case of SCF (SCF skp2 ), or WD-40 repeatcontaining proteins such as Cdh1 or Cdc20 in case of APC (APC Cdh1 , APC Cdc20 ).
Many SCF substrates are phosphorylated prior to ligase recognition. The degradation of cyclin D1 is initiated upon phosphorylation of Thr-286 by GSK-3b (Diehl et al., 1997 (Diehl et al., , 1998 . Cyclin E/Cdk2 complexes can initiate cyclin E degradation via phosphorylation of Thr-380, thus forming a negative feedback loop to limit cyclin E expression to late G 1 (Clurman et al., 1996; Won & Reed, 1996) . Degradation of p27 is initiated by cyclin E/Cdk2-catalysed phosphorylation of Thr-187 (Vlach et al., 1997) . The APC mediates degradation of cyclin A after nuclear envelope breakdown in prometaphase, while cyclin B1 degradation occurs during the metaphase to anaphase transition (Clute & Pines, 1999; den Elzen & Pines, 2001; Geley et al., 2001) Interestingly, the APC is activated upon phosphorylation of APC core subunits by Cdk2 and Cdk1 itself (Morgan, 1999) . Thus, protein degradation is initiated by cell cycle proteins, ensuring timed regulation of protein activity.
Is v-cyclin more stable than cyclin D? v-Cyclin does not contain residues homologous to the C-terminal cyclin D1 Thr-286 residue or cyclin E Thr-380 residue that have been implicated in the destruction of these cyclins. However, a direct comparison of the stability of v-cyclin compared with cyclin D1 has not yet been performed.
G 1 /S progression
The retinoblastoma protein
The most recognized function of cyclin D/Cdk activity is inactivation of the Rb tumour suppressor. Rb and its relatives p107 and p130 are called 'pocket' proteins , reflecting the folding of conserved domains around a pocket that constitutes the proteinbinding site. The most established function of pocket proteins is interaction with and inhibition of the E2F family of transcription factors. Rb is thought to repress E2F-dependent transcription by at least two mechanisms. First, Rb directly binds the transactivation domain of E2F, thus blocking recruitment of the transcription machinery (Helin et al., 1993) . Secondly, Rb binding to E2F actively represses transcription via its interaction with factors that influence chromatin structure. These include histone deacetylases (HDACs) (Kouzarides, 1999) and components of the SWI/SNF chromatinremodelling complex (Dunaief et al., 1994; Singh et al., 1995; Zhang et al., 2000) . Together, these factors mediate tight assembly of chromatin in nucleosomes, inhibiting access of the transcriptional apparatus.
Rb contains 16 potential Cdk phosphorylation sites, which regulate the binding of distinct proteins (Knudsen & Wang, 1997) . Complete phosphorylation of Rb relieves its binding to E2F, triggering E2F-dependent transcription of G 1 /S genes. Successive phosphorylation by cyclin D/Cdk complexes in early G 1 and cyclin E/Cdk2 complexes in late G 1 is necessary for hyperphosphorylation of Rb (Lundberg & Weinberg, 1998) , and phosphorylation by cyclin A/Cdk2 may maintain Rb hyperphosphorylation during S phase (Sherr, 1996) . Although based on overexpression studies, a potential model is that phosphorylation by cyclin D/Cdk4 first disrupts the association of Rb with HDAC, thereby allowing cyclin E expression. The interaction between Rb and SWI/SNF is, however, maintained and is sufficient to repress the cyclin A promoter. Upon phosphorylation by cyclin E/Cdk2, Rb repression of the cyclin A promoter is relieved (Harbour et al., 1999; Zhang et al., 2000) , ensuring orderly activation of cyclin E and A in S phase.
The E2F family of transcription factors
The E2F family of transcription factors regulates the transcription of genes involved in cell cycle progression, nucleotide biosynthesis and DNA replication. Six E2F family proteins exist (E2F1-6) which heterodimerize with DP proteins (DP1 and DP2) in all possible combinations (Trimarchi & Lees, 2002) . E2F4 and E2F5 in complex with p130 mediate the transcriptional repression of E2F-responsive genes in quiescent or differentiated cells (Trimarchi & Lees, 2002) . In contrast, E2F1, E2F2 and E2F3 are expressed specifically in dividing cells where they interact with Rb and p107. They are potent transcriptional activators and cells lacking expression of E2F1, E2F2 and E2F3 are unable to proliferate (Wu et al., 2001) , confirming their role in S-phase progression.
The complexity of E2F-triggered responses is illustrated by results from microarray analyses (Ishida et al., 2001; Muller et al., 2001) , which identified E2F-induced genes that function during mitosis (e.g. Cdc2 and cyclin B), as well as genes involved in apoptosis and development. In addition, analysis of E2F-repressed genes in quiescent cells identified mitotic genes, including regulators of cytokinesis (e.g. polo-kinase), chromosome condensation and segregation (e.g. securin) (Ren et al., 2002) . These results suggest a broader role for E2Fs in mitosis as well as G 1 /S.
Orderly progression through G 1 /S phases
A (simplified) scheme of G 1 /S progression can be drawn based on the assimilation of the previous information (Fig. 5) Interestingly, cyclin E, but not cyclin D, is required for G 1 /S progression in cells lacking Rb function (Ohtsubo et al., 1995) and cyclin E overexpression is sufficient to overcome growth arrest induced by a phosphorylation-resistant Rb mutant (Lukas et al., 1997) . This implies that the main downstream target of cyclin D/Cdk activity is Rb, while cyclin E/Cdk2 has additional S-phase targets. Indeed, cyclin E, like cyclin A, triggers phosphorylation of DNA replication proteins such as Cdc6, directly activating DNA replication (Bell & Dutta, 2002 ). This simple model is, however, challenged by findings that mice lacking cyclin E1 and E2 or Cdk2 expression are viable and that cell cycle progression is uncompromised in cells derived from these mice (Berthet et al., 2003; Geng et al., 2003; Ortega et al., 2003) . Specific cyclin/Cdk activities may therefore exhibit previously unappreciated functional redundancies.
Active cyclin D/E-and A-dependent kinases are regulated by negative feedback loops: cyclin E/Cdk2 complexes phosphorylate cyclin E, directing it to SCF-mediated ubiquitination. Cyclin A/Cdk2 phosphorylation of components of the APC may initiate proteolysis of cyclin A itself. Importantly, E2Fs are inactivated around S/G 2 by at least two mechanisms. First, cyclin A/Cdk2 phosphorylation of E2F1 inhibits its DNA binding activity (Krek et al., 1994) . Secondly, E2F1 undergoes SCF Skp2 -dependent ubiquitination and degradation (Marti et al., 1999) . Negative regulation of G 1 /S progression can also be enforced upon CKI induction, for example upon the execution of checkpoints.
v-Cyclin expression deregulates G 0 /G 1 /S control v-Cyclin/Cdk complexes exhibit properties that extend those of cellular cyclins and potentially enable productive KSHV propagation. It is unknown whether KSHV infects proliferating progenitor or resting quiescent cells that contain high levels of CKIs. If the latter is true, then v-cyclin could still form active complexes with endogenous Cdks and stimulate exit from G 0 . In addition, its broadened substrate specificity to include G 1 -and S-phase targets would allow progression through G 1 and initiation of S phase. Functional studies support this hypothesis, as v-cyclin expression induces S-phase entry in quiescent cells and in p16-or p27-overexpressing, G 1 -arrested cells (Swanton et al., 1997) . Furthermore, the evasion of Cdk inhibition by v-cyclin/Cdk complexes would be beneficial in case of the activation of anti-viral tumour suppressor pathways by the host cell. Importantly, transgenic expression of v-cyclin promotes tumorigenesis (Verschuren et al., 2002) , showing that v-cyclin has intrinsic oncogenic properties that can enhance host cell proliferation.
v-Cyclin/Cdk6 phosphorylation of replication proteins may also directly control DNA replication. Indeed, addition of v-cyclin, but not cyclin D, to isolated G 1 nuclei triggered replication initiation in a manner analogous to cyclin A (Laman et al., 2001) . Initiation starts with the assembly of pre-replicative complexes at replication origins in a reaction known as 'licensing' (Bell & Dutta, 2002) . Further elucidation of DNA replication mechanisms in human cells will clarify how v-cyclin controls origin licensing and/or firing.
Cell cycle progression upon v-cyclin expression still relies on the host cell cycle machinery. Cells expressing a p27 T187A mutant that cannot be degraded cannot complete S phase even when v-cyclin is expressed (Ellis et al., 1999; Mann et al., 1999) . This implies that activation of endogenous Cdks upon p27 degradation is required for full S-phase progression. Complementing these data, v-cyclin expression is unable to bypass a block on endogenous Cdk2 imposed by the chemical Cdk inhibitor roscovitine or by dominant-negative Cdk2 (Ellis et al., 1999) . Another factor is the dependence of v-cyclin/Cdk activity on CAK phosphorylation by endogenous enzyme (Jeffrey et al., 2000; Kaldis et al., 2001) . Thus, v-cyclin expression is likely to create an environment that is more conducive to (viral) DNA replication, but requires endogenous cyclin/Cdk activity for full cell cycle progression.
G 2 /M progression
Mitotic entry
Mitotic events such as nuclear envelope breakdown coincide with cyclin B/Cdk1 nuclear import (Hagting et al., 1999) . Cyclin B nuclear localization is thought to be initiated upon its phosphorylation by cyclin B/Cdc2 itself or polo-kinase (Plk). Plk phosphorylation of Cdc25C also stimulates the dephosphorylation of inhibitory phosphates on Cdk2, further enhancing cyclin B/Cdk1 activity (Kumagai & Dunphy, 1996; Qian et al., 2001) (Fig. 6) . Targets of cyclin B/Cdc2 include structural proteins and nucleolar proteins that regulate nuclear envelope breakdown and spindle assembly (Nigg, 1993) .
Mitotic exit
Mitotic exit is triggered by the APC Cdc20 -dependent destruction of securin protein, which is required for sister chromatid separation (Nasmyth, 2002) . In addition, degradation of cyclins A and B is essential for mitotic progression beyond anaphase (Morgan, 1999) , as illustrated by findings that non-degradable versions of cyclin A and B arrest cells in metaphase or anaphase (Geley et al., 2001; Parry & O'Farrell, 2001; Sigrist et al., 1995) . Mitotic cyclin degradation is coordinated by the sequential activation of the APC Cdc20 and APC Cdh1 and, again, oscillations in kinase activity are key (Harper et al., 2002) . First, the APC Cdc20 complex is activated upon phosphorylation by Plk and cyclin B/Cdk1. This may increase the binding of the Cdc20 adaptor to APC and stimulate APC Cdc20 activity towards degradation of cyclins A and B. Plk thus acts as a master regulator of mitosis through triggering both the activation and degradation of cyclin B. Secondly, cyclin A/Cdk2 phosphorylation of Cdh1 inhibits Cdh1 binding to APC and the degradation of cyclin A therefore licenses activation of APC Cdh1 and complete degradation of mitotic cyclins (Lukas et al., 1999) (Fig. 6) . Thirdly, cytokinesis is executed upon removal of inhibitory phosphates on Cdh1 and cyclin B/Cdk1 mitotic substrates by the Cdc14 phosphatase (Visintin et al., 1998) .
Although securin and mitotic cyclins are the best understood APC substrates, a large number of other proteins are degraded by the APC. Examples are Plks themselves and Aurora protein kinases (Bischoff & Plowman, 1999) . Both kinases localize to mitotic structures such as centrosomes, which constitute the microtubule organizing centres of the cell (Doxsey, 2001; Hinchcliffe & Sluder, 2001 ) and mitotic spindles. Deregulation of Aurora and Plk kinases disrupts mitotic exit (Meraldi et al., 2002) , and the ability of APC Cdh1 to keep their levels in check is therefore important for a proper execution of cytokinesis.
v-Cyclin expression deregulates mitotic progression
v-Cyclin-expressing cells undergo continued DNA synthesis and nuclear division, yet do not undergo cytokinesis (Verschuren et al., 2002) . Thus v-cyclin/Cdk complexes, as well as deregulating G 1 /S progression, also deregulate mitosis. The cytokinesis defect may involve v-cyclinassociated misexpression of mitotic regulators, most likely through an increase of E2F transcriptional targets. Indeed, defects in cell division and concomitant multinucleation have been reported upon overexpression of Plk and Aurora kinases (Meraldi et al., 2002; Mundt et al., 1997; Wang et al., 2002) . However, the mechanistic explanation of these results remains unknown.
An outcome of mitotic deregulation in v-cyclin-expressing cells is activation of the p53 tumour suppressor, triggering apoptosis and growth arrest (Verschuren et al., 2002) . Activation of p53 occurs in an E2F1-and p19
ARF -independent manner and may instead occur as a response to the formation of tetraploid cells. Active p53 would normally trigger a G 1 arrest via induction of p21 protein and consequent G 1 /S Cdk inhibition (Stewart & Pietenpol, 2001 ). However, v-cyclin/Cdk complexes are refractory to Cdk inhibitors, which most likely explains why v-cyclin-expressing cells become polyploid. The increase in ploidy correlates with an increase in the number of centrosomes, explained by the co-regulation of the centrosome duplication and DNA replication cycles (Hinchcliffe & Sluder, 2001) . A second outcome of mitotic deregulation is therefore the induction of genomic instability through centrosome amplifications and consequent spindle defects.
SUMMARY AND PERSPECTIVES
v-Cyclin/Cdk complexes exhibit properties that could stimulate the expansion of KSHV-infected cells (Fig. 7) . These include functions that deregulate G 1 /S progression, such as enhanced kinase activity towards Rb, a promiscuous substrate specificity, escape from inhibition by CKIs and initiation of DNA replication. In addition, v-cyclin/Cdk activity may promote genomic instability by disrupting mitotic progression. Counteracting these pro-tumorigenic stimuli, v-cyclin expression sensitizes cells to undergo apoptosis (Ojala et al., 1999; Verschuren et al., 2002) , in part by inactivating the anti-apoptotic cellular Bcl-2 pool (Ojala et al., 2000) , and triggers a p53-dependent growth arrest (Verschuren et al., 2002) . v-Cyclin-expressing cultured cells only survive and expand as an aneuploid population when p53 is inactive. These findings are confirmed in vivo, as Em v-cyclin expression drives lymphomagenesis only when the p53 pathway is disrupted (Verschuren et al., 2002) , probably via allowing the expansion of a genetically altered population of lymphocytes (Verschuren et al., 2004) . A remaining quest is to translate these findings into a physiological role for v-cyclin in KSHV-associated pathogenesis. This is complicated by the lack of a KSHVpermissive system or animal models for pathogenesis. Mutant viruses lacking the expression of the MHV68 viral cyclin show normal latent infection patterns, but inefficient reactivation from latency (Hoge et al., 2000; van Dyk et al., 2000) . However, thus far MHV68 cyclin is the only viral cyclin studied in an in vivo context and no deductions for persistent KSHV infection in a physiological context can be made.
Interesting but largely speculative topics of discussion concern the interplay between virally expressed genes. The majority of tumour cells in KSHV-associated diseases are latently infected, with only 1-3 % of the cells showing lytic replication (Zhong et al., 1996) . Latent gene expression is highly restricted and encompasses an 'oncogenic cluster' of three genes with overlapping transcripts: latency-associated nuclear antigen (LANA), v-cyclin and viral FLICE-inhibitory protein (v-FLIP) (Jenner et al., 2001; Paulose-Murphy et al., 2001 ). In addition, several RNA transcripts encoding interferon regulatory factors (IRFs) are detected. Since latent gene expression is widespread in KSHV diseases, the combination of latent protein expression may be critical for oncogenesis.
An in vivo functional interaction may exist between the latent proteins LANA and ORF K10 IRF, which bind and inhibit p53 (Friborg et al., 1999; Rivas et al., 2001) , and v-cyclin. Indeed, LANA colocalizes with p53 in KS samples (Katano et al., 2001) . This, together with the absence of recurrent p53 mutations in KSHV-associated disorders (Carbone et al., 1998; Katano et al., 2001; Kennedy et al., 1998) , raises the intriguing possibility that v-cyclin-induced apoptosis and/or growth arrest are inhibited by these proteins. Secondly, LANA binds the Rb protein and activates E2F-dependent transcription (Radkov et al., 2000) , and LANA negatively regulates GSK-3b function to increase b-catenin protein stability and transcriptional activity (Fujimuro et al., 2003) , constituting further proliferative stimuli that could enhance v-cyclin function. Related to this, inhibition of GSK-3b by LANA could promote the nuclear localization of cellular cyclin D. Thirdly, latent expression of v-FLIP may cooperate with v-cyclin to promote KSHV tumorigenesis via its ability to inhibit death receptor-triggered lymphocyte apoptosis (Djerbi et al., 1999) .
The establishment of KSHV gene functions in vivo is further complicated by the fact that infected cells may support the growth of uninfected cells in trans (Ensoli & Sturzl, 1998) . Endothelial cells expressing the KSHVencoded G protein-coupled receptor (GPCR), for example, cooperate with cells expressing v-cyclin in sarcomagenesis through paracrine mechanisms (Montaner et al., 2001) . This emphasizes the need to assess KSHV gene function in a physiological context. While 10 % of spindle cells in early KS lesions are KSHVpositive (Dupin et al., 1999) , around 90 % of the spindle cells in late stage nodular lesions are KSHV-infected, suggesting that the virus provides a growth advantage to infected cells (Boshoff & Weiss, 2001) . Furthermore, KS and PEL begin as polyclonal hyperplasias that develop into monoclonal tumours (Gill et al., 1998; Judde et al., 2000) . The all-encompassing question is therefore whether v-cyclin expression promotes the tumorigenic evolution of KSHV-infected cells by triggering genomic instability and clonal outgrowth of cells with an enhanced proliferative capacity.
